Search

Objective Distinguishing bacterial, viral, or other etiologies of acute illness is diagnostically challenging with significant implications for appropriate antimicrobial use. Host gene expression offers a promising approach, although no clinically useful test has been developed yet to accomplish this. Here, Qvella's FAST HR (Richmond Hill, Ontario, Canada) process was developed to quantify previously identified host gene expression signatures in whole blood in <45 minutes. Method Whole blood was collected from 128 human subjects (mean age 47, range 18–88) with clinically adjudicated, microbiologically confirmed viral infection, bacterial infection, noninfectious illness, or healthy controls. Stabilized mRNA was released from cleaned and stabilized RNA-surfactant complexes using e-lysis, an electrical process providing a quantitative real-time reverse transcription polymerase chain reaction-ready sample. Threshold cycle values (CT) for 10 host response targets were normalized to hypoxanthine phosphoribosyltransferase 1 expression, a control mRNA. The transcripts in the signature were specifically chosen to discriminate viral from nonviral infection (bacterial, noninfectious illness, or healthy). Classification accuracy was determined using cross-validated sparse logistic regression. Results Reproducibility of mRNA quantification was within 1 cycle as compared to the difference seen between subjects with viral versus nonviral infection (up to 5.0 normalized CT difference). Classification of 128 subjects into viral or nonviral etiologies demonstrated 90.6% overall accuracy compared to 82.0% for procalcitonin (P =.06). FAST HR achieved rapid and accurate measurement of the host response to viral infection in less than 45 minutes. Conclusions These results demonstrate the ability to translate host gene expression signatures to clinical platforms for use in patients with suspected infection. Clinical Trials Registration NCT00258869. [ABSTRACT FROM AUTHOR]

The author explains the value of publishing protocols of clinical trials. Among the benefits of publishing study protocols are informed decision making for patients, minimized bias, accountability on the part of authors, opportunity for the scientific community to evaluate the consistency of investigators' intent, and dissemination of contemporary ideas with respect to study design and data analysis. The criteria for the publication of a proposed study are cited.

The article announces the adoption of the position of the International Committee of Medical Journal Editors (ICMJE) which requires the mandatory registration of all clinical trials in Great Britain by the member journals of the Surgical Journal Editors Group (SJEG). The SJEG advocates the idea of promoting a publicly accessible clinical trial database. The member journals of the SJEG will require registration of prospective clinical trials starting July 1, 2007.